Abstract
The aim of reverse pharmacognosy is to find new biological targets for natural compounds by virtual or real screening and identify natural resources that contain the active molecules. To demonstrate the applicability of this concept, we report here a study on εviniferin, an active ingredient for cosmetic development. Nevertheless, this natural substance is weakly defined in terms of biological properties. SELNERGY, an inverse docking computer software, was used to identify putative binding biological targets for εviniferin. Among the 400 screened proteins two targets were retained. For cosmetic application, cyclic nucleotide phosphodiesterase 4 (PDE4) was the most interesting candidate. Moreover, other PDE subtypes (1, 2, 3, 5 and 6) were not retained, indicating a selectivity for PDE4. The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of εviniferin for the PDE4 subtype. This selectivity was confirmed by evaluation of εviniferin on the secretion of TNF-α and Interleukin-8. Our data demonstrated that εviniferin possesses anti-inflammatory properties by inhibiting PDE4 subtype. In conclusion, reverse pharmacognosy and its inverse docking component cannot only be integrated into a program for new lead discovery but is also a useful approach to find new applications for identified compounds.
Keywords: Inverse docking, cosmetics, cyclic nucleotide phosphodiesterases, viniferin, selnergy
Current Drug Discovery Technologies
Title: Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Volume: 2 Issue: 3
Author(s): Quoc-Tuan Do, Isabelle Renimel, Patrice Andre, Claire Lugnier, Christian D. Muller and Philippe Bernard
Affiliation:
Keywords: Inverse docking, cosmetics, cyclic nucleotide phosphodiesterases, viniferin, selnergy
Abstract: The aim of reverse pharmacognosy is to find new biological targets for natural compounds by virtual or real screening and identify natural resources that contain the active molecules. To demonstrate the applicability of this concept, we report here a study on εviniferin, an active ingredient for cosmetic development. Nevertheless, this natural substance is weakly defined in terms of biological properties. SELNERGY, an inverse docking computer software, was used to identify putative binding biological targets for εviniferin. Among the 400 screened proteins two targets were retained. For cosmetic application, cyclic nucleotide phosphodiesterase 4 (PDE4) was the most interesting candidate. Moreover, other PDE subtypes (1, 2, 3, 5 and 6) were not retained, indicating a selectivity for PDE4. The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of εviniferin for the PDE4 subtype. This selectivity was confirmed by evaluation of εviniferin on the secretion of TNF-α and Interleukin-8. Our data demonstrated that εviniferin possesses anti-inflammatory properties by inhibiting PDE4 subtype. In conclusion, reverse pharmacognosy and its inverse docking component cannot only be integrated into a program for new lead discovery but is also a useful approach to find new applications for identified compounds.
Export Options
About this article
Cite this article as:
Do Quoc-Tuan, Renimel Isabelle, Andre Patrice, Lugnier Claire, Muller D. Christian and Bernard Philippe, Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin, Current Drug Discovery Technologies 2005; 2 (3) . https://dx.doi.org/10.2174/1570163054866873
DOI https://dx.doi.org/10.2174/1570163054866873 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment
Current Pharmaceutical Design Phytochemicals Resveratrol and Sulforaphane as Potential Agents for Enhancing the Anti-Tumor Activities of Conventional Cancer Therapies
Current Pharmaceutical Biotechnology Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Hyperthermia Associated Osteonecrosis in Young Patients with Pelvic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?
Reviews on Recent Clinical Trials Therapeutic Potential of Endophytic Compounds: A Special Reference to Drug Transporter Inhibitors
Current Topics in Medicinal Chemistry Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology